Skip to content
Home/Companies/Biotech/Dilepix
Dilepix

Dilepix

Biotech·France·Active·6yr hold
Entry
2020
Hold
6yr
Status
Active

Who owns Dilepix?

Dilepix is a French Biotech company, currently owned by Elaia Partners since 2020.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Elaia Partners
Investor
Elaia Partners
Elaia Alpha II · 2020 · VC

Key facts

HQFrance
SectorBiotech
Websitewww.dilepix.com

More from Elaia Alpha II

Other portfolio companies in the same fund.

Alice & Bob
Alice & Bob
Active
Deep TechFrance· 2022
Arsen
Arsen
Active
CybersecurityFrance· 2022
Aviwell
Active
BiotechUS· 2022
Corporatings
Corporatings
Active
Data & AnalyticsFrance· 2022
Giskard
Giskard
Active
AI/MLFrance· 2022
Kheops
Kheops
Active
Data & AnalyticsFrance· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Dilepix?

Dilepix is currently owned by Elaia Partners, through Elaia Alpha II, since 2020.

When did Elaia Partners acquire Dilepix?

Elaia Partners acquired Dilepix in 2020.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue